The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy

Hypermorphic mutation of phospholipase C,  2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

(2015) T.-M. Liu et al.   BLOOD

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

(2015) C. Sun et al.   BLOOD

CXCL13 antibody for the treatment of autoimmune disorders

(2015) Ekaterina Klimatcheva et al.   BMC IMMUNOLOGY

Function and regulation of self-reactive marginal zone B cells in autoimmune arthritis

(2015) Anna-Karin E Palm et al.   Cellular & Molecular Immunology

Bruton’s Tyrosine Kinase Synergizes with Notch2 To Govern Marginal Zone B Cells in Nonobese Diabetic Mice

(2015) James B. Case et al.   JOURNAL OF IMMUNOLOGY

Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus

(2015) Christopher M Tipton et al.   NATURE IMMUNOLOGY

X-linked agammaglobulinemia in two siblings with a novel mutation in theBTKgene who presented with polyarticular juvenile idiopathic arthritis

(2015) T Patiroglu et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Ibrutinib for the treatment of Waldenström macroglobulinemia

(2015) Rajshekhar Chakraborty et al.   Expert Review of Hematology

Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants

(2014) Linda M Hartkamp et al.   ANNALS OF THE RHEUMATIC DISEASES

Structural evaluation of BTK and PKCδ mediated phosphorylation of MAL at positions Tyr86 and Tyr106

(2014) Rehan Zafar Paracha et al.   COMPUTATIONAL BIOLOGY AND CHEMISTRY

Ibrutinib: First Global Approval

(2014) Fiona Cameron et al.   DRUGS

Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation

(2014) Vassilios Lougaris et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Autoimmunity and Inflammation in X-linked Agammaglobulinemia

(2014) Vivian P. Hernandez-Trujillo et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Dual Functions of Bruton's Tyrosine Kinase and Tec Kinase during Fc  Receptor-Induced Signaling and Phagocytosis

(2014) J. Jongstra-Bilen et al.   JOURNAL OF IMMUNOLOGY

Bruton's Tyrosine Kinase Promotes Persistence of Mature Anti-Insulin B Cells

(2014) R. H. Bonami et al.   JOURNAL OF IMMUNOLOGY

Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis

(2014) Yan Lou et al.   JOURNAL OF MEDICINAL CHEMISTRY

Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors

(2014) S Cheng et al.   LEUKEMIA

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib Resistance in Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pre-B Cell Receptor Signaling Induces Immunoglobulin κ Locus Accessibility by Functional Redistribution of Enhancer-Mediated Chromatin Interactions

(2014) Ralph Stadhouders et al.   PLOS BIOLOGY

Suppression of Glomerulonephritis in Lupus-Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase

(2013) Paola Mina-Osorio et al.   ARTHRITIS AND RHEUMATISM

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

(2013) B. Y. Chang et al.   BLOOD

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease

(2013) Donna K. Finch et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells

(2013) Jingming Wang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Specific peripheral B cell tolerance defects in patients with multiple sclerosis

(2013) Tuure Kinnunen et al.   JOURNAL OF CLINICAL INVESTIGATION

Ibrutinib and novel BTK inhibitors in clinical development

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis

(2013) A. L. Rankin et al.   JOURNAL OF IMMUNOLOGY

Tolerant Anti-Insulin B Cells Are Effective APCs

(2013) P. L. Kendall et al.   JOURNAL OF IMMUNOLOGY

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

(2013) Susan O'Brien et al.   LANCET ONCOLOGY

Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel small molecule therapeutics in rheumatoid arthritis

(2013) V. Kelly et al.   RHEUMATOLOGY

Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory Diseases

(2013) L. Vargas et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

IL-10-producing regulatory B cells (B10 cells) in autoimmune disease

(2013) Ioannis Kalampokis et al.   ARTHRITIS RESEARCH & THERAPY

Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials

(2013) Jan A. Burger   Current Hematologic Malignancy Reports

Expansion of Autoreactive Unresponsive CD21−/lowB Cells in Sjögren's Syndrome-Associated Lymphoproliferation

(2012) D. Saadoun et al.   ARTHRITIS AND RHEUMATISM

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice

(2012) L. P. Kil et al.   BLOOD

Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders

(2012) Tadeusz Robak et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Increased Pro-inflammatory Cytokine Production After Lipopolysaccharide Stimulation in Patients with X-linked Agammaglobulinemia

(2012) María Edith González-Serrano et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

(2012) Jack Hutcheson et al.   ARTHRITIS RESEARCH & THERAPY

Anergic Responses Characterize a Large Fraction of Human Autoreactive Naive B Cells Expressing Low Levels of Surface IgM

(2011) T. D. Quach et al.   JOURNAL OF IMMUNOLOGY

Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy

(2011) L. Liu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk

(2011) Xingguang Liu et al.   NATURE IMMUNOLOGY

More than just B-cell inhibition

(2011) Eric M Ruderman et al.   ARTHRITIS RESEARCH & THERAPY

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

(2011) Betty Y Chang et al.   ARTHRITIS RESEARCH & THERAPY

The Role of Bruton's Tyrosine Kinase in B-Cell Development and Function in Mice and Mana

(2010) WASIF N. KHAN et al.   Annals of the New York Academy of Sciences

Genes on the X chromosome affect development of collagen-induced arthritis in mice

(2010) L. JANSSON et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Constitutive activation of Bruton's tyrosine kinase induces the formation of autoreactive IgM plasma cells

(2010) Rogier Kersseboom et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

CXCL13 Blockade Disrupts B Lymphocyte Organization in Tertiary Lymphoid Structures without Altering B Cell Receptor Bias or Preventing Diabetes in Nonobese Diabetic Mice

(2010) R. A. Henry et al.   JOURNAL OF IMMUNOLOGY

Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis

(2010) Julie A Di Paolo et al.   Nature Chemical Biology

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reduced Diabetes in btk-Deficient Nonobese Diabetic Mice and Restoration of Diabetes with Provision of an Anti-Insulin IgH Chain Transgene

(2009) P. L. Kendall et al.   JOURNAL OF IMMUNOLOGY

Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells

(2008) Kristina E. Halcomb et al.   MOLECULAR IMMUNOLOGY